Orginal Article |
|
|
|
|
抗体药物免疫原性评估的研究进展 |
杜力,刘晓志,高健,王志明() |
华北制药集团新药研究开发有限责任公司 抗体药物研制国家重点实验室 石家庄 050015 |
|
Research Progress on Immunogenicity Evaluation of Antibodies |
Li DU,Xiao-zhi LIU,Jian GAO,Zhi-ming WANG() |
New Drug Research and Development Company Ltd. ,North China Pharmaceutical Corporation,Shijiazhuang 050015,China |
引用本文:
杜力,刘晓志,高健,王志明. 抗体药物免疫原性评估的研究进展[J]. 中国生物工程杂志, 2018, 38(2): 89-94.
Li DU,Xiao-zhi LIU,Jian GAO,Zhi-ming WANG. Research Progress on Immunogenicity Evaluation of Antibodies. China Biotechnology, 2018, 38(2): 89-94.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20180213
或
https://manu60.magtech.com.cn/biotech/CN/Y2018/V38/I2/89
|
[1] |
Mazur M Olek-hrak K Karczewski J K , et al. Biosimilars in dermatology. Postepy Dermatologii Alergologii, 2015,32(5):384-387.
|
[2] |
Kurki P, Van Aerts L, Wolff-Holz E , et al. Interchangeability of Biosimilars. A European Perspective, 2017,31(2):83-91.
|
[3] |
Karalis V D . From bioequivalence to biosimilarity: The rise of a novel regulatory framework. Drug Research, 2016,66(1):1-6.
doi: 10.1055/s-0042-117071
|
[4] |
Girault D, Trouvin J H, Blachier-Poisson C , et al. Biosimilars: from technical to pharmacoeconomic considerations. Therapie, 2015,70(1):47-55.
doi: 10.2515/therapie/2015003
|
[5] |
Dranitsaris G, Dorward K, Hatzimichael E , et al. Clinical trial design in biosimilar drug development. Investigational New Drugs, 2013,31(2):479-487.
doi: 10.1007/s10637-012-9899-2
pmid: 23161336
|
[6] |
Anh D D, Thiem V D, Anh N T , et al. Randomized safety and immunogenicity trial of a seasonal trivalent inactivated split virion influenza vaccine (IVACFLU-S) in healthy young Vietnamese adults. The Lancet Infectious Diseases, 2016,34(45):5457-5462.
doi: 10.1016/j.vaccine.2016.08.052
pmid: 27567493
|
[7] |
Rispens T, Hart M H Ooijevaar-De Heer P et al. Drug interference in immunogenicity assays depends on valency. Journal of Pharmaceutical and Biomedical Analysis, 2013,85:179-185.
doi: 10.1016/j.jpba.2013.07.022
pmid: 23954437
|
[8] |
Skinner S R, Szarewski A, Romanowski B , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet (London, England), 2014,384(9961):2213-2227.
doi: 10.1016/S0140-6736(14)60920-X
|
[9] |
Van Brummelen E M, Ros W, Wolbink G , et al. Antidrug antibody formation in oncology: clinical relevance and challenges. Vaccine, 2016,21(10):1260-1268.
doi: 10.1634/theoncologist.2016-0061
pmid: 5061540
|
[10] |
Vezer B, Buzas Z, Sebeszta M , et al. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Current Medical Research and Opinion, 2016,32(5):829-834.
doi: 10.1185/03007995.2016.1145579
pmid: 26808864
|
[11] |
Deehan M, Garces S, Kramer D , et al. Managing unwanted immunogenicity of biologicals. Autoimmunity Reviews, 2015,14(7):569-574.
doi: 10.1016/j.autrev.2015.02.007
pmid: 25742758
|
[12] |
Wheeler C M, Skinner S R Del Rosario-Raymundo M R , et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, 2016,16(10):1154-1168.
|
[13] |
Vultaggio A, Petroni G, Pratesi S , et al. How the immune system responds to therapeutic biological agents. The Journal of International Medical Research, 2016,44(1 suppl):38-42.
doi: 10.1177/0300060515593248
pmid: 27683137
|
[14] |
Halim L A, Brinks V, Jiskoot W , et al. Quality and batch-to-batch consistency of original and biosimilar epoetin products. Journal of Pharmaceutical Sciences, 2016,105(2):542-550.
doi: 10.1016/j.xphs.2015.10.019
pmid: 26869417
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|